Scandinavian ChemoTech AB

CMOTEC B

SE0009242654

Advanced Medical Equipment & Technology

Market Closed - Nasdaq Stockholm Other stock markets 11:11:16 2024-04-26 am EDT			5-day change	1st Jan Change
2.24 ^SEK	-1.32%		0.00%	-17.04%

Apr. 22	Scandinavian Chemotech AB Obtains Approval of the Third and Last Patent Application in India	CI
Apr. 10	Scandinavian ChemoTech AB Attains Progress by Obtaining Patent Protection for Two Essential Patents in India	CI

Scandinavian ChemoTech AB Announces Lars Hedbys Declines Re-Election as a Member of the Board

April 14, 2023 at 04:30 am EDT

Scandinavian ChemoTech AB (publ) announced that Lars Hedbys does not wish to run for re-election as a member and is making his seat available.

Latest news about Scandinavian ChemoTech AB

Scandinavian Chemotech AB Obtains Approval of the Third and Last Patent Application in India	Apr. 22	CI
Scandinavian ChemoTech AB Attains Progress by Obtaining Patent Protection for Two Essential Patents in India	Apr. 10	CI
Scandinavian ChemoTech Secures Order from the Largest European Equine Clinic	Mar. 27	CI
Scandinavian ChemoTech AB's IQwave Receives Certification for Tumour Treatment in Singapore	Mar. 25	CI
Scandinavian ChemoTech AB Signs New Agreement with Chhatrapati Shivaji Subharti Hospital & Medical College	Mar. 20	CI
Scandinavian ChemoTech AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 05	CI
Scandinavian ChemoTech AB Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 05	CI
Scandinavian ChemoTech AB Receives Order for USD 30,000 from One of Its Largest Clients in the United States	Feb. 12	CI
Transcript : Scandinavian ChemoTech AB - Special Call	Jan. 29
Scandinavian ChemoTech's Animal Care Division Receives an Order from A Leading Veterinary Hospital in South Florida, USA	Dec. 15	CI
Scandinavian ChemoTech Expects to Sign Three New Commercial Contracts in Fourth of 2023	Dec. 11	CI
Scandinavian Chemotech Thanks for the Cooperation with Its IR Consultant Who Leaves the Management Team	Nov. 30	CI
Scandinavian ChemoTech AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	23-10-17	CI
Scandinavian Chemotech AB Animal Care Division Receives Additional Order from Existing Customer	23-10-12	CI
Scandinavian ChemoTech's Subsidiary for Animal Care in the USA Receives Additional Orders for TSE Treatment Kits	23-10-04	CI
Scandinavian Chemotech Foresees Higher Future Revenues After Signing A Third Commercial Contract in India	23-09-29	CI
Scandinavian Chemotech Signs Distribution Agreement for Chile with Lambertis Corporation Sa	23-09-18	CI
Scandinavian ChemoTech AB Expands its Cooperation with Gamma Gurus Pty Ltd in Australia to Include Human Care	23-08-30	CI
Scandinavian ChemoTech AB's Subsidiary VQ Anim Care e Inc. Receives Order Confirmation for a VeterinaryIQure System to Ohio	23-08-18	CI
Scandinavian ChemoTech AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-15	CI
Scandinavian ChemoTech AB Receives a Patent in Japan for its Unique Tumor-Specific and Dynamic Cancer Treatment	23-07-17	CI
Scandinavian ChemoTech AB Renews Existing Loans from External Lenders, Larger Shareholders and Members of the Board and CEO	23-07-12	CI
ChemoTech's Animal Care Division Wins Supplier Contract with Medvet; Receives an SEK 1.3 Million Order in the USA	23-06-20	CI
Robin Sukhia Elects as the New Chairman of the Board for Scandinavian ChemoTech AB	23-06-14	CI
Scandinavian ChemoTech AB Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-25	CI

Chart Scandinavian ChemoTech AB

Duration

Period

More charts

Scandinavian ChemoTech AB is a Sweden-based company, which is primarily engaged in the healthcare industry. The Company is focused on cancer treatment and manufactures specialized medical equipment. The Company's product IQWave is an electrochemotherapy (ECT) device. The IQWave system enhances the effects of the chemotherapeutic substance by opening up small pores in the tumor cells, giving the injected chemotherapeutic substance (no more than 15 IU of bleomycin) direct access to the DNA of the target cells. Among the product's applications are hypernephroma, kaposi sarcoma, transitional cell carcinoma, head and neck squamous cell carcinoma, malignant melanoma, basal cell carcinoma. The treatment can be used for cutaneous as well as subcutaneous tumors.

Sector

Advanced Medical Equipment & Technology

Calendar

2024-05-13 - Q1 2024 Earnings Release

More about the company

Sector Other Advanced Medical Equipment & Technology

	1st Jan change	Capi.
SCANDINAVIAN CHEMOTECH AB	-17.04%	3.66M
THERMO FISHER SCIENTIFIC	+8.07%	219B
DANAHER CORPORATION	+6.59%	183B
INTUITIVE SURGICAL, INC.	+11.26%	133B
BOSTON SCIENTIFIC CORPORATION	+26.57%	108B
SIEMENS HEALTHINEERS AG	+0.65%	63.06B
EDWARDS LIFESCIENCES CORPORATION	+13.35%	52.02B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	-0.62%	48.2B
AGILENT TECHNOLOGIES, INC.	-0.93%	40.37B
GE HEALTHCARE TECHNOLOGIES INC.	+11.54%	39.35B

Other Advanced Medical Equipment & Technology